Drug intelligence / Profile preview

CT-02

Development stage: Preclinical
Lead developer: Captor Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

CT-02 is a preclinical drug candidate developed by Captor Therapeutics SA. It functions as a degradable molecular glue, specifically targeting and inducing the proteolysis of NIMA-related kinase 7 (NEK7). This mechanism is being investigated for its potential in treating various conditions, including neoplasms, immune system diseases, and hemic and lymphatic diseases, with active indications in autoimmune diseases and hematologic neoplasms.

Other names: CTA-02CTA02CTA 02

Targets

NEK7 (NIMA-related kinase 7)

Beyond the preview

Go deeper on CT-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-02.

Explore the full profile